A Phase I Trial of Lenvatinib (Multi-kinase Inhibitor) and Capecitabine (Anti-metabolite) in Patients With Advanced Malignancies

Trial Profile

A Phase I Trial of Lenvatinib (Multi-kinase Inhibitor) and Capecitabine (Anti-metabolite) in Patients With Advanced Malignancies

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs Capecitabine (Primary) ; Lenvatinib (Primary)
  • Indications Biliary cancer; Bone cancer; Breast cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Glioma; Liver cancer; Lymphoma; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Rectal cancer; Renal cancer; Solid tumours; Thyroid cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 23 Jun 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 10 Jun 2017 Biomarkers information updated
    • 29 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top